Liver cancer therapy company Sirtex Medical said it's expanding its operations in the U.S. by boosting sales, marketing, and functional support staff at its Massachusetts headquarters and in regional offices across the country.
The expansion is part of a global growth plan that began in July 2010 and comes on the heels of record growth in U.S. dose sales for its SIR-Spheres microspheres, according to the vendor.
SIR-Spheres microspheres are cleared for use in Australia, the European Union, and the U.S. To date, more than 20,000 doses of the microspheres have been supplied to more than 400 cancer treatment centers worldwide, Sirtex said.
